header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

REDUCED BONE MINERAL DENSITY IS SIGNIFICANTLY ASSOCIATED WITH REDUCED HIP JOINT SPACE WIDTH IN WOMEN RESULTS FROM THE COPENHAGEN OSTEOARTHRITIS STUDY



Abstract

Background/Objective: Since estrogen receptors (ERα/ERβ) were identified in human chondrocytes, animal-and experimental studies have demonstrated the importance of continued estrogen production for the integrity of articular cartilage. However, human epidemiological support of the hypothesis has been inconclusive. The present study investigated the relationship between reduced bone mineral densities (BMD), as a surrogate parameter of endogenous estrogen status – assessed by digital x-ray radiogrammetry (DXR), and reduced minimum hip joint space width (JSW).

Methods: Standardised hand radiographs of the Copenhagen Osteoarthritis Study cohort of 3.913 adults (1.470M/2.443F) with a mean age of 60 years (range, 18–92), were analysed by the X-Posure digital software v. 2.0 (Sectra-Pronosco). The system is operator independent. From 1.200 individual measurements per radiograph mean BMD was calculated. Minimum hip joint JSW was assessed in standardized, pelvic radiographs.

Results: DXR-BMD decreased in both men and women after the age of 45 years, progressively more so in women. While minimum hip JSW in men remained relatively unaltered throughout life, a marked decline in female minimum hip JSW after 45 years was observed. We found moderate, but highly significant relationships between reduced BMD and reduced hip JSW in women (p < 0.001), adjusted for age and dysplastic joint incongruity.

Conclusion: We believe that the present study supports the hypothetical relationship between reduced estrogen levels and hip joint space width reduction in women.

Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland